Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Liabilities and Shareholders Equity: 2023-2024

Historic Liabilities and Shareholders Equity for Inhibrx Biosciences (INBX) over the last 2 years, with Dec 2024 value amounting to $180.8 million.

  • Inhibrx Biosciences' Liabilities and Shareholders Equity fell 20.26% to $177.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $813.0 million, marking a year-over-year change of. This contributed to the annual value of $180.8 million for FY2024, which is 41.29% down from last year.
  • Latest data reveals that Inhibrx Biosciences reported Liabilities and Shareholders Equity of $180.8 million as of FY2024, which was down 41.29% from $307.9 million recorded in FY2023.
  • In the past 5 years, Inhibrx Biosciences' Liabilities and Shareholders Equity ranged from a high of $307.9 million in FY2023 and a low of $180.8 million during FY2024.
  • Its 2-year average for Liabilities and Shareholders Equity is $244.3 million, with a median of $244.3 million in 2023.
  • Data for Inhibrx Biosciences' Liabilities and Shareholders Equity shows a maximum YoY tumbled of 41.29% (in 2024) over the last 5 years.
  • Over the past 2 years, Inhibrx Biosciences' Liabilities and Shareholders Equity (Yearly) stood at $307.9 million in 2023, then crashed by 41.29% to $180.8 million in 2024.